Home > Insider Trading > Filing (0001104659-16-131412)

Filing Details

Accession Number:: 0001104659-16-131412
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-07-07 06:04:02
Reporting Period:: 2016-07-06

Filing Date:: 2016-07-07
Accepted Time:: 2016-07-07 06:04:02
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1556263	Syros Pharmaceuticals Inc.	SYRS	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1222012	Noubar Afeyan	1 Memorial Drive #7 Cambridge MA 02142	No	No	Yes	No
1255927	Jr M Edwin Kania	1 Memorial Drive #7 Cambridge MA 02142	No	No	Yes	No
1503559	Flagship Ventures Fund Iv, L.p.	1 Memorial Drive #7 Cambridge MA 02142	No	No	Yes	No
1508051	Flagship Ventures Fund Iv General Partner Llc	1 Memorial Drive #7 Cambridge MA 02142	No	No	Yes	No
1590973	Flagship Ventures Fund Iv-Rx, L.p.	1 Memorial Drive #7 Cambridge MA 02142	No	No	Yes	No
1642578	Flagship Venturelabs Iv, Llc	1 Memorial Drive #7 Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2016-07-06	213,333	$0.00	213,333	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	53,333	$0.00	53,333	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	1,066,666	$0.00	1,279,999	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	266,666	$0.00	319,999	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	1,600,000	$0.00	2,879,999	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	400,000	$0.00	719,999	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	474,661	$0.00	3,354,660	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	118,665	$0.00	838,664	No	4	C	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	320,000	$12.50	3,674,660	No	4	P	Indirect	See Footnote
Common Stock	Acquisiton	2016-07-06	80,000	$12.50	918,664	No	4	P	Indirect	See Footnote

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	C	Indirect	See Footnote
No	4	P	Indirect	See Footnote
No	4	P	Indirect	See Footnote

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A-1 Preferred Stock	Disposition	2016-07-06	800,000	$0.00	213,333	$0.00
Common Stock	Series A-1 Preferred Stock	Disposition	2016-07-06	200,000	$0.00	53,333	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2016-07-06	4,000,000	$0.00	1,066,666	$0.00
Common Stock	Series A-2 Preferred Stock	Disposition	2016-07-06	1,000,000	$0.00	266,666	$0.00
Common Stock	Series A-3 Preferred Stock	Disposition	2016-07-06	6,000,000	$0.00	1,600,000	$0.00
Common Stock	Series A-3 Preferred Stock	Disposition	2016-07-06	1,500,000	$0.00	400,000	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	1,779,981	$0.00	474,661	$0.00
Common Stock	Series B Preferred Stock	Disposition	2016-07-06	444,995	$0.00	118,665	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	213,332	Indirect	See Footnote

Footnotes

The Series A-1 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-1 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series A-2 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-2 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series A-3 Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A-3 Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The Series B Preferred Stock converted into Common Stock on a 3.75-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons other than Flagship IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Stephane Bancel, a director of the Issuer, is a limited partner of Flagship IV and a member of Flagship IV LLC. Mr. Bancel disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV-Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons other than Flagship IV-Rx disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Stephane Bancel, a director of the Issuer, is a member of Flagship IV LLC. Mr. Bancel disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.
Held by Flagship VentureLabs IV, LLC ("VentureLabs IV"). Flagship IV is the manager of VentureLabs IV. Flagship IV LLC is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV, Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by VentureLabs IV. Each of the filing persons other than VentureLabs IV disclaims beneficial ownership of the shares except to the extent of his or its pecuniary interest therein. Stephane Bancel, a director of the Issuer, is a limited partner of Flagship IV and a member of Flagship IV LLC. Mr. Bancel disclaims beneficial ownership of the shares except to the extent of his pecuniary interest therein.